OXULAR-LIMITED
24.1.2023 14:01:39 CET | Business Wire | Press release
Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND enables advancement of the OXEYE Phase 2 trial, which will evaluate the safety and efficacy of OXU-001 and the potential to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory treatment for high-prevalence retinal disorders, beginning with DME.
OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres®. OXU-001 will be delivered to the posterior suprachoroidal space of the eye via Oxulumis®, Oxular’s proprietary illuminated microcatheter. This in-office treatment could lead to enhanced efficacy, favorable tolerability, and extended durability to address key unmet needs for people with DME and other retinal disorders.
In 12-month preclinical studies, OXU-001 was well-tolerated and related pharmacokinetic data confirmed that therapeutic drug levels were consistently maintained in target retinal tissues. These data suggest that a single treatment of OXU-001 may provide up to twelve-month treatment effects with an improved clinical safety profile.
“The IND clearance for OXU-001 marks a significant milestone for Oxular,” said Thomas Cavanagh, Chief Executive Officer of Oxular. “DME is the most common and sight-threatening complication of diabetic eye disease and can be debilitating for patients who are often of working age. Today’s treatment approaches have limited durability, requiring frequent anti-VEGF injections into the eye. Also, typically more than two OZURDEX® implants per year may be required. The opportunity to provide patients with a targeted, in-office treatment just once a year could be a game-changer for this prevalent disease. We look forward to advancing OXU-001 into the clinic and evaluating its therapeutic impact in 2023.”
About Oxular
Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. The company has engineered sustained-release drug formulations designed to last up to one year following single dosing and delivery technology to access tissues in the posterior suprachoroidal space via routine, in-office administration. This unique combination aims to substantially improve patients’ vision by increasing therapeutic effectiveness, while reducing side-effects and minimizing the frequency of treatments. Oxular is developing a deep portfolio of product candidates that includes treatments for prevalent retinal diseases, such as diabetic macular edema and diabetic retinopathy. For more information, please visit Oxular.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005116/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Releases Global Study on Scaling Enterprise AI, Highlighting the Shift from Pilots to Platform-Driven Transformation8.7.2026 09:08:00 CEST | Press release
As artificial intelligence moves from experimentation into the core of enterprise operations, a new reality is emerging: scaling AI is no longer a technology challenge, but a transformation imperative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708088519/en/ FPT Corporation today announced the release of a global thought leadership study, titled “From Pilots to Reusable Platforms: A Blueprint for Scaling Enterprise AI.” Published on 08 July 2026, this is a commissioned study conducted by Forrester Consulting on behalf of FPT, examining how enterprises across regions and industries are advancing their AI journeys - and why many remain unable to translate early momentum into consistent, enterprise-wide impact. The executive study is based on a global survey of 397 business and technology decision-makers globally, supported by in-depth interviews with senior executives across North America, Europe, Asia Pacific and Japan
Rubrik Security Cloud Launches on the AWS European Sovereign Cloud8.7.2026 09:00:00 CEST | Press release
The launch will allow highly regulated European Union organisations to meet strict EU data residency requirements Rubrik, the Security and AI Operations Company, today announced the availability of Rubrik Security Cloud on the AWS European Sovereign Cloud, providing the European Union (EU) public sector and highly regulated private organisations with a cloud-native path for sovereign cyber resilience. Organisations increasingly require resilience measures that are sovereign, not just contractually compliant. Rubrik Security Cloud on the AWS European Sovereign Cloud meets this demand. It will allow highly regulated industries, such as banking, utilities, healthcare, and government, to leverage the full power of AWS, while meeting stringent data residency requirements within the European Union (EU). Advanced security features on a fully featured, independently operated sovereign cloud The AWS European Sovereign Cloud is a fully featured, independently operated sovereign cloud backed by s
Wolters Kluwer Brings Libra AI Workflows Into One for Italian Legal Professionals8.7.2026 09:00:00 CEST | Press release
Building on Libra by Wolters Kluwer’s early leadership, strong market momentum and advanced AI innovation in Italy, its capabilities are now directly available in One via the Libra add-in. Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in One, its leading legal research platform in Italy. This step further reinforces the strong commercial success and rapid market adoption of the Libra legal AI workspace in the country. With the integration generative AI features are directly available in the research workflow of legal professionals allowing a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Italy in February, setting a new benchmark for AI-enabled legal research by combining advanced AI capabilities with authoritative and trusted legal content from One and supporting lawyers across their full workflow, from research to analysis and document drafting. With
Flix and Klarna Expand Partnership to Give Millions of Travelers Across the U.S. and Europe More Ways to Pay8.7.2026 09:00:00 CEST | Press release
Flix and Klarna, the global digital bank and flexible payments provider, today announced an expanded partnership that brings more flexible payment options to millions of travelers across its platforms. Beginning today, Klarna will be available in 21 Flix markets, adding the UK, Germany, Italy, France, Poland, Switzerland, Austria, and Spain, among others, to its existing presence in the U.S. and Sweden. With Klarna now embedded directly into the Flix booking flow, passengers have three new ways to pay: in full at the time of booking, in interest-free installments, or through longer-term financing for larger purchases. For cross-border journeys, Klarna removes foreign exchange fees, letting travelers pay in their local currency with no hidden conversion costs. Klarna users will also receive exclusive deals when booking through Flix platforms. "Travel is one of the biggest spending categories in people's lives, yet flexibility at checkout has lagged behind,” said David Sykes, Chief Comme
Record Launches "Record Amanah" Sharia-Compliant Investment Platform8.7.2026 09:00:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce the launch of Record Amanah, its dedicated platform for Sharia-compliant investment solutions. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The launch follows a series of successful Sharia-compliant transactions completed by Record, most recently for a client in Brunei, and reflects growing demand from institutional investors seeking investment opportunities that combine attractive risk-adjus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom